Drugs that contain Fosdenopterin Hydrobromide

1. List of Nulibry drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7504095 SENTYNL THERAPS INC Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency
Jan, 2025

(1 year, 11 months from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 26, 2028
New Chemical Entity Exclusivity (NCE) Feb 26, 2026

NCE-1 date: February, 2025

Market Authorisation Date: 26 February, 2021

Treatment: Method of treating molybdenum cofactor deficiency type a

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic